Clinical Trials

Treatment-Naïve CLL: Phase 3 Study of Sonrotoclax Plus Zanubrutinib Compared With Venetoclax Plus Obinutuzumab in Participants With TN Chronic Lymphocytic Leukemia (CELESTIAL)

The CELESTIAL study is a multi-center randomized phase III trial to compare the efficacy of sonrotoclax plus zanubrutinib versus venetoclax plus obinutuzumab in participants with chronic lymphocytic leukemia. In this study, participants with CLL, without prior treatment will receive either venetoclax plus obinutuzumab combination treatment that is considered a standard first line treatment or receive…

Continue reading

A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer (RAMP 301)

This international, randomized, open-label, Phase 3 study will compare the investigational combination of avutometinib plus defactinib versus Investigator’s Choice of Treatments (ICT) in patients with recurrent LGSOC who have progressed on a prior platinum-based therapy. Avutometinib and defactinib are both a type of drug called a kinase inhibitor. Kinase inhibitors block cancer cell growth. The…

Continue reading

A Phase III Randomized Trial Comparing Unrelated Donor Bone Marrow Transplantation with Immune Suppressive Therapy for Newly Diagnosed Pediatric and Young Adult Patients with Severe Aplastic Anemia

This study is a multi-center randomized phase III trial to compare the failure free survival between those randomized to IST vs 9-10/10 HLA matched URD BMT. The study will address patient-reported outcomes and gonadal function in each arm and explore critical biological correlates including assessing germline genetic mutations associated with pediatric SAA that may lead…

Continue reading
Abbvie

Abbvie Clinical Trials for Myelofibrosis and Acute Myeloid Leukemia

Myelofibrosis Transform-1 (M16-191) Phase 3 Study Of Navitoclax In Combination With Ruxolitinib Versus Ruxolitinib In Subjects With Myelofibrosis FL sites: Lynn Cancer Institute in Boca FCS South FCS East FCS North gov: https://www.clinicaltrials.gov/ct2/show/NCT04472598 Acute Myeloid Leukemia Viale-T (M19-063) Phase 3 Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine After Allogeneic Stem Cell…

Continue reading
UF Health Cancer Center

UF Health Cancer Center Clinical Trials

With more than 150 clinical trials open and currently recruiting patients, the UF Health Center has numerous options for patients with refractory malignancies. The February issue of the UF Health Cancer Center Navigator highlights a few of them. For a complete listing of trials available through our system, please click below. View all UF Health…

Continue reading

Gainesville Cancer Center Offers Community Trial Navigation for Local Clinical Research Trials

GAINESVILLE, FL – March 28th, 2018. . . . Florida Cancer Specialists & Research Institute (FCS), is pleased to announce the availability of a local Trial Navigator at Gainesville Cancer Center(GCC), located at 6420 W. Newberry Road, East Wing-Suite 100, Gainesville, FL.  Offering comprehensive care and a wide range of treatments, Gainesville Cancer Center has an established record of broad clinical research…

Continue reading

ENVISION Phase 3 Study

Evaluating the effect of givosiran (ALN-AS1) on the rate of porphyria attacks in patients with Acute Hepatic Porphyrias (AHP). Trial Status: Enrolling Interested in learning more? Please email us at clinicaltrials@alnylam.com For more info: ClinicalTrials.gov – NCT03338816

Continue reading

New Data vs Bicalutamide

Indication XTANDI (enzalutamide) capsules is indicated for the treatment of patients with metastatic castration-resistant prostate cancer (CRPC). Important Safety Information Contraindications  XTANDI is not indicated for women. XTANDI can cause fetal harm and potential loss of pregnancy. Warnings and Precautions Seizure occurred in 0.5% of patients receiving XTANDI in clinical studies. In placebo-controlled studies, 8 of 1671…

Continue reading

AbbVie and Bristol-Myers Squibb Announce Oncology Clinical Collaboration to Evaluate the Combination of Rova-T plus Opdivo and Opdivo + Yervoy Regimen

  AbbVie and Bristol-Myers Squibb Company  announced a clinical trial collaboration to evaluate the safety, tolerability and efficacy of AbbVie’s investigational biomarker-specific antibody drug conjugate Rova-T (rovalpituuzumab tesirine) in combination with Bristol-Myers Squibb’s Opdivo (nivolumab) and Opdivo + Yervoy (ipilimumab) regimen as a treatment for relapsed extensive-stage small cell lung cancer (SCLC). The Phase 1/2…

Continue reading

New Gynecologic Oncology Clinical Trials Sylvester Comp Cancer Center Sylvester Comp Cancer Center

The Sylvester Comprehensive Cancer Center’s Division of Gynecologic Oncology’s Research Program is opening 4 new clinical trials for women with ovarian, cervical and endometrial cancer. These include two surgical trials evaluating the role of sentinel lymph node biopsy in cervical and endometrial cancer and two immunotherapy trials in first-line and recurrent ovarian cancer. They continue…

Continue reading

Available Clinical Trials at UF Health Cancer Center

UF Health Cancer Center has several clinical trials in process, below please find information about four trials that are currently accepting participants: ADU-CL-11 A Phase 1/2, Open-Label Safety and Efficacy Evaluation of CRS-207 in Combination With Epacadostat in Adults With Platinum-Resistant Ovarian, Fallopian, or Peritoneal Cancer. https://clinicaltrials.gov/ct2/show/NCT02575807?term=adu-cl-11&rank=1  ARGO A Phase III Randomized Placebo-Controlled Study Evaluating…

Continue reading

Florida Hospital Clinical Trial GL-ONC1-015: Phase 1b Study with GL-ONC1 Oncolytic Immunotherapy in Patients with Platinum-resistant or Refractory Ovarian Cancer

New Clinical Trials Available at FHCI: Ovarian Cancer and peritoneal carcinomatosis: GL-ONC1-015: This is an open-label, non-randomized Phase 1b study evaluating the safety and immunotherapeutic effect of GL-ONC1, an oncolytic vaccinia virus, in women diagnosed with platinum-resistant ovarian cancer and peritoneal carcinomatosis. GL-ONC1 is administered via an intraperitoneal catheter. https://clinicaltrials.gov/ct2/show/NCT02759588?term=GL-ONC1&rank=2   Clinical Trial Profile: Clinical…

Continue reading
UF Health

The UF Health Cancer Center Clinical Trial mobile app is here!

NaviGATOR makes it easier to search for and find clinical trials that fit you and your patients’ needs. This powerful and easy-to-navigate application helps you quickly learn about the availability of clinical trials from UF Health Cancer Center. And with one-tap your patient can be referred to UF Health Cancer Center. [su_button url=”http://trials.cancer.ufl.edu/” target=”blank” style=”flat”…

Continue reading
lynn cancer institute

Lynn Cancer Institute Oncology Trials

Clinical Trials – November 2015 Eugene M. and Christine E. Lynn Office of Research Administration 561.955.4800 Center for Hematology-Oncology 561.955.6400 Radiation Oncology 561.955.4111 BREAST Primary Site Sponsor/Study ID NCT # Protocol Description Eligibility Breast HER2 + MBC third line PUMA- NER-1301 NALA NCT01808573 A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients…

Continue reading
spohnc

Support for People With Oral and Head and Neck Cancer

“Find a Clinical Trial for Oral, Head and Neck Cancer” Call toll-free 844-432-3888 (Mon-Fri, 9 am -5 pm ET) SPOHNC is pleased to introduce EmergingMed’s Clinical Trial Navigation Service. We want you to be aware of all of your treatment options. SPOHNC has partnered with EmergingMed to offer you a way to take action. The…

Continue reading

Afatinib versus Erlotinib as Second-line Treatment Phase III Clinical Trial Update

Afatinib versus Erlotinib as Second-line Treatment Phase III Clinical Trial Update Boehringer Ingelheim Pharmaceuticals, Inc. would like to share the overall survival (OS) data from a head-to-head Phase III clinical trial that was recently published in The Lancet Oncology. The study evaluated the company’s lung cancer treatment as a potential option for patients with advanced…

Continue reading

Head-to-Head Efficacy and Safety Results in First-Line CLL

CLL-11: Designed to determine the superior anti-CD20 regimen for typical* patients1-4 CLL-11 is a Phase III trial that evaluated GAZYVA + Clb against rituximab + Clb to establish a first-line treatment for typical CLL patients, based on age and coexisting medical conditions1-4 The safety and efficacy of GAZYVA + Clb was evaluated in a Stage…

Continue reading

© 2021 FLASCO | Premium Website Design by The HDG